New diagnostic methods for pancreatic cancer using portal vein blood
Establish a Diagnostic Model Based on Multiple Molecule Profiling and Certain Established Markers for Identification of Pancreatic Cancer
This study is testing new ways to diagnose pancreatic cancer using blood samples from the portal vein to see if it can help doctors find cancer earlier and more accurately.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Changhai Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT04536220 on ClinicalTrials.gov |
What this trial studies
This study aims to explore innovative diagnostic markers derived from portal venous blood samples to enhance the identification of malignant pancreatic masses. By utilizing endoscopic ultrasound to collect blood from the portal vein, the study seeks to leverage advanced techniques such as ctDNA analysis, metabolomics, and exosome profiling to improve diagnostic accuracy. The goal is to address the limitations of current diagnostic methods, which often lead to missed diagnoses and delayed treatment. This approach is designed to provide a less invasive and more informative means of diagnosing pancreatic cancer.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18-75 with a diagnosis or suspicion of a solid pancreatic mass larger than 1 cm.
Not a fit: Patients with pancreatic cystic lesions or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly improve the early and accurate diagnosis of pancreatic cancer, leading to better patient outcomes.
How similar studies have performed: While the use of portal vein blood for diagnostic purposes is a novel approach, similar studies have shown promise in enhancing diagnostic accuracy for other conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. age 18-75 years,male or female 2. diagnosis or suspection of solid pancreatic mass based on previous imaging examination (ultrasonography, CT or MRI) 3. lesion diameter larger than 1 cm 4. signed informed consent letter Exclusion Criteria: 1. pregnant female 2. Pancreatic cystic lesions 3. Anticoagulant/antiplatelet therapy cannot be suspended 4. unable or refuse to provide informed consent 5. Coagulopathy (platelet count \< 50× 103/μL,international normalized ratio \> 1.5) 6. Severe cardiopulmonary dysfunction that cannot tolerate intravenous anesthesia 7. with history of mental disease 8. other medical conditions that are not suitable for EUS-FNA
Where this trial is running
Shanghai, Shanghai Municipality
- Changhai Hospital — Shanghai, Shanghai Municipality, China (Recruiting)
Study contacts
- Principal investigator: Kaixuan Wang, MD — Changhai Hospital
- Study coordinator: Xiangyu Kong, MD
- Email: xiangyukong185@hotmail.com
- Phone: 13564644397
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.